Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1140MR)

This product GTTS-WQ1140MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1140MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2266MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ13484MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ3738MR IVTScrip™ mRNA-Anti-TFPI, BAY-1093884(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY-1093884
GTTS-WQ15504MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ11968MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ10790MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ9273MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-130
GTTS-WQ6004MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CNTO 095
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW